InvestSMART

Amplia Therapeutics Limited (ASX: ATX) - Announcements

- Current share price for ATX : $0.140

ASX company news and announcements for Amplia Therapeutics Limited (ATX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Amplia Therapeutics Limited (ATX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Amplia Therapeutics Limited (ATX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Amplia Therapeutics Limited (ATX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$72 Bioshares Biotech Summit Presentation 6 Aug 2026 10:09AM $0.160 $0.140 fallen by 12.50%
$72 Amplia signs Collaboration and Supply Agreement with Lilly 4 Aug 2026 8:22AM $0.135 $0.140 risen by 3.70%
$72 Scientific Paper Studies of narmafotinib - Pancreatic Cancer 31 Jul 2026 8:33AM $0.125 $0.140 risen by 12%
$72 Quarterly Activities/Appendix 4C Cash Flow Report 29 Jul 2026 8:29AM $0.130 $0.140 risen by 7.69%
$72 Notice of Annual General Meeting/Proxy Form 27 Jul 2026 4:14PM $0.130 $0.140 risen by 7.69%
$72 Notification regarding unquoted securities - ATX 15 Jul 2026 6:27PM $0.135 $0.140 risen by 3.70%
$72 Notification regarding unquoted securities - ATX 15 Jul 2026 6:18PM $0.135 $0.140 risen by 3.70%
$72 Amplia Therapeutics Shareholder Webinar 13 Jul 2026 9:37AM $0.145 $0.140 fallen by 3.45%
$72 Initial Director's Interest Notice - Brett Carter 6 Jul 2026 4:43PM $0.155 $0.140 fallen by 9.68%
$72 Amplia Announces Appointment of Brett Carter to Board 6 Jul 2026 8:52AM $0.150 $0.140 fallen by 6.67%
$72 Annual General Meeting to be held Friday 28 August 2026 1 Jul 2026 8:20AM $0.145 $0.140 fallen by 3.45%
$72 Amplia Announces Changes to Board's Leadership Roles 30 Jun 2026 8:18AM $0.150 $0.140 fallen by 6.67%
$72 Notice of Initial Substantial Holding from SOL 25 Jun 2026 8:17AM $0.125 $0.140 risen by 12%
$72 Becoming a substantial holder from PCG 24 Jun 2026 2:51PM $0.130 $0.140 risen by 7.69%
$72 Appendix 4G - Key to Corporate Governance Disclosures 29 May 2026 3:38PM $0.140 $0.140 fallen by 0%
$72 Corporate Governance Statement 2026 29 May 2026 1:43PM $0.138 $0.140 risen by 1.82%
$72 Preliminary Final Report and Annual Report YE 31 March 2026 29 May 2026 1:37PM $0.138 $0.140 risen by 1.82%
$72 Amplia Launches First Stage of Pivotal Narmafotinib Trial 19 May 2026 8:18AM $0.140 $0.140 fallen by 0%
$72 Notice under Section 708A(5)(e) of the Corporations Act 12 May 2026 3:49PM $0.150 $0.140 fallen by 6.67%
$72 Application for quotation of securities - ATX 12 May 2026 3:28PM $0.150 $0.140 fallen by 6.67%
$72 Amplia and ANZGOG announce Ovarian Cancer Study 8 May 2026 8:29AM $0.135 $0.140 risen by 3.70%
$72 Quarterly Activities/Appendix 4C Cash Flow Report 28 Apr 2026 9:38AM $0.165 $0.140 fallen by 15.15%
$72 ACCENT Trial Mature Data Presented at AACR Conference 22 Apr 2026 8:26AM $0.155 $0.140 fallen by 9.68%
$72 Amplia MD Responds to Questions Regarding AMPLICITY Trial 8 Apr 2026 2:06PM $0.155 $0.140 fallen by 9.68%
$72 Amplia Therapeutics Halts Recruitment in AMPLICITY Trial 7 Apr 2026 8:40AM $0.240 $0.140 fallen by 41.67%

1 - 25 of 538 results

Page 1 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.